In VivoThe promise of mRNA therapeutics has been held back by a fundamental physical limitation: lipid nanoparticles containing mRNA are inherently fragile and prone to aggregation when subjected to the mech
Pink SheetThe US Food and Drug Administration’s June user fee goal calendar reflects the gravitational pull of major meetings. The month opens with the monster American Society of Clinical Oncology annual meeti
Pink SheetConfused and alarmed stakeholders worry that Health and Human Services Secretary Robert F. Kennedy Jr. usurped a role long played by the US Centers for Disease Control and Prevention and its external
Pink SheetContract manufacturing of biologics is one of the few weak points in the typically overwhelming advantage the US holds over Europe in bestowing the first approval for new drug products, a Pink Sheet